Julie Feder
Director of Finance/CFO bij AURA BIOSCIENCES, INC.
Vermogen: 1 M $ op 31-03-2024
Profiel
Julie B.
Feder is the Chief Financial Officer at Aura Biosciences, Inc. She previously held the same position at Verastem, Inc. and Clinton Health Access Initiative.
Prior to that, she worked as a Senior Manager at Deloitte & Touche LLP and as Vice President-Internal Audit at Genzyme Corp.
Feder received her undergraduate degree from Sy Syms School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
AURA BIOSCIENCES INC
0.27% | 01-02-2024 | 134 276 ( 0.27% ) | 1 M $ | 31-03-2024 |
Actieve functies van Julie Feder
| Bedrijven | Functie | Begin |
|---|---|---|
| AURA BIOSCIENCES, INC. | Director of Finance/CFO | 01-08-2018 |
Eerdere bekende functies van Julie Feder
| Bedrijven | Functie | Einde |
|---|---|---|
| VERASTEM, INC. | Director of Finance/CFO | 01-06-2018 |
Clinton Health Access Initiative
 Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Director of Finance/CFO | 01-07-2017 |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Corporate Officer/Principal | 01-01-2008 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | - |
Opleiding van Julie Feder
| Sy Syms School of Business | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| VERASTEM, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Commercial Services |
